Skip to main content
Back to all tickers

Vistagen Therapeutics, Inc. (VTGN) stock forecast & analysis

0.1831

NasdaqCM · USDDelayed by 15 minutes

Down: -0.0013, -0.7%

2 analyses

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for VTGN.US from 2026-05-12 to 2026-11-10 with 0 analysis runs marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Open
0.1825
Previous close
0.1844
Day range
0.1760 – 0.1879
52-week range
0.1600 – 5.14
Volume (shares)
541.89K
Net assets
Not available
Expense ratio
Not available
Shares outstanding
44.38M
P/E ratio
Not available
Dividend yield
0.00%
Beta
0.47
Market cap
8.13M
Market Scanner’s AI analysis of Vistagen Therapeutics, Inc. (VTGN), updated September 2026: Vistagen's Fasedienol study data and significant short-term price gains contrasted with long-term technical weakness and ongoing unprofitability.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Vistagen Therapeutics, Inc. (VTGN) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

Vistagen's Fasedienol study data and significant short-term price gains contrasted with long-term technical weakness and ongoing unprofitability.

Recent analyses for Vistagen Therapeutics (VTGN) covered positive clinical data for its drug Fasedienol, alongside substantial short-term stock price appreciation. The reports also detailed significant year-over-year revenue growth, though the company remains unprofitable with negative operating margins and returns on equity. Technical indicators present a mixed picture, with strong recent momentum but also signs of being overbought in the short term and a pronounced long-term downtrend.

VTGN news & sentiment

News reports highlighted positive clinical trial data for Vistagen's Fasedienol, alongside significant short-term stock price gains. Social media discussions reflected this positive news flow, with sentiment appearing to align with the encouraging clinical updates and price action.

VTGN technical picture

Short-term price action showed significant gains, with the price trading above its 50-day SMA and 10-day EMA. However, long-term trends indicated weakness, with the price well below its 200-day SMA. Momentum indicators suggested the stock was overbought in the short term, while longer-term indicators pointed to a downtrend.

Fundamentals

The company demonstrated significant year-over-year quarterly revenue growth. Despite this revenue increase, Vistagen Therapeutics remains unprofitable with negative operating margins and returns on equity, and reported net losses in its latest annual and quarterly statements. The company holds a substantial cash position with healthy current and quick ratios.

Factors discussed — upside

  • Positive subgroup data from Fasedienol Phase 3 studies for social anxiety disorder.
  • Significant year-over-year quarterly revenue growth of 504.9%.
  • Strong short-term price momentum indicated by 7-day and 30-day changes.
  • Price trading above the 50-day SMA, indicating a positive medium-term trend.
  • Healthy current and quick ratios suggesting good liquidity.

Factors discussed — risks

  • Significant long-term price weakness indicated by a substantial 91-day decline.
  • Price trading significantly below the 200-day SMA, indicating a strong long-term downtrend.
  • Company remains unprofitable with negative operating margins and return on equity.
  • High RSI and MFI readings indicating short-term overbought conditions.
  • Price trading above the upper Bollinger Band, signaling potential overextension.
  • Clinical trial data
  • Revenue growth
  • Profitability
  • Technical indicators

Summary updated .

VTGN technical indicators

Common technical indicators for VTGN, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average0.23Price below
10-day exponential moving average0.18Price above
Relative strength index (14-day)41.76Neutral
MACD line (12/26/9)-0.0171Above its signal line
Bollinger bands (20-day, 2σ)0.15 – 0.21Price inside the bands

Frequently asked questions

What is the bull case for Vistagen Therapeutics, Inc.?
The bull case for Vistagen Therapeutics (VTGN) centers on positive clinical trial data for its drug Fasedienol, which has shown promise in treating social anxiety disorder. This is complemented by significant year-over-year revenue growth and strong recent price momentum, with the stock trading above its 50-day moving average.
What are the risks for Vistagen Therapeutics, Inc.?
Risks for Vistagen Therapeutics (VTGN) include substantial long-term price weakness and the stock trading below its 200-day moving average, despite recent gains. The company continues to report net losses and negative operating margins, and current technical indicators suggest the stock may be overextended in the short term.
Is Vistagen Therapeutics, Inc. bullish or bearish?
Recent AI analyses of Vistagen Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for Vistagen Therapeutics (VTGN) centers on positive clinical trial data for its drug Fasedienol, which has shown promise in treating social anxiety disorder. This is complemented by significant year-over-year revenue growth and strong recent price momentum, with the stock trading above its 50-day moving average. Discussed risks: Risks for Vistagen Therapeutics (VTGN) include substantial long-term price weakness and the stock trading below its 200-day moving average, despite recent gains. The company continues to report net losses and negative operating margins, and current technical indicators suggest the stock may be overextended in the short term. These are descriptive observations, not a recommendation.
What is the latest sentiment on Vistagen Therapeutics, Inc.?
News reports highlighted positive clinical trial data for Vistagen's Fasedienol, alongside significant short-term stock price gains. Social media discussions reflected this positive news flow, with sentiment appearing to align with the encouraging clinical updates and price action.
How does Market Scanner analyse Vistagen Therapeutics, Inc.?
Every analysis of Vistagen Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Vistagen Therapeutics, Inc.?

The bull case for Vistagen Therapeutics (VTGN) centers on positive clinical trial data for its drug Fasedienol, which has shown promise in treating social anxiety disorder. This is complemented by significant year-over-year revenue growth and strong recent price momentum, with the stock trading above its 50-day moving average.

What are the risks for Vistagen Therapeutics, Inc.?

Risks for Vistagen Therapeutics (VTGN) include substantial long-term price weakness and the stock trading below its 200-day moving average, despite recent gains. The company continues to report net losses and negative operating margins, and current technical indicators suggest the stock may be overextended in the short term.

Is Vistagen Therapeutics, Inc. bullish or bearish?

Recent AI analyses of Vistagen Therapeutics, Inc. examined factors on both sides. Discussed upside: The bull case for Vistagen Therapeutics (VTGN) centers on positive clinical trial data for its drug Fasedienol, which has shown promise in treating social anxiety disorder. This is complemented by significant year-over-year revenue growth and strong recent price momentum, with the stock trading above its 50-day moving average. Discussed risks: Risks for Vistagen Therapeutics (VTGN) include substantial long-term price weakness and the stock trading below its 200-day moving average, despite recent gains. The company continues to report net losses and negative operating margins, and current technical indicators suggest the stock may be overextended in the short term. These are descriptive observations, not a recommendation.

What is the latest sentiment on Vistagen Therapeutics, Inc.?

News reports highlighted positive clinical trial data for Vistagen's Fasedienol, alongside significant short-term stock price gains. Social media discussions reflected this positive news flow, with sentiment appearing to align with the encouraging clinical updates and price action.

How does Market Scanner analyse Vistagen Therapeutics, Inc.?

Every analysis of Vistagen Therapeutics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.

Read the methodology

Bundles used
gemini-low-v2

Run a fresh VTGN.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 2 earlier reports



Most analyzed tickers